Leap Therapeutics, Inc.
LPTXNext catalyst
DKN-01
Colorectal Cancer
Get an email about LPTX's next catalysts
Track Leap Therapeutics (LPTX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 0 past
DKN-01 Phase 2 Est. Readout
Estimated primary completion for DKN-01 trial (NCT05761951) in Endometrial Cancer. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
DKN-01 | Phase 2 | Colorectal Cancer | - | - |
Frequently asked questions
What is in Leap Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Leap Therapeutics, Inc.'s (LPTX) pipeline across Phase 2. Its lead program is DKN-01 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Leap Therapeutics, Inc.'s next FDA catalyst?→
Leap Therapeutics, Inc.'s (LPTX) next tracked catalyst is a Phase 2 readout expected January 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track LPTX biotech catalysts?→
Add LPTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Leap Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.